



MARKET ACCESS ADVICE

Reference Number: MAA1717
Date of Issue: 22/02/2017
Date of Effect: Immediate

China: Re-commencement of trade in finished bovine blood and blood products

Attention	Industries	Export Establishments Industry bodies – Serum industry, AMIC, MLA Licensed exporters	
	Department of Agriculture and Water Resources	Central and Regional Offices ATMs and FOMs OPVs and Meat inspection staff	
Affected Markets		China	
Further Information		Name: Emily Orchard-Mills Email: emily.orchard-mills@agriculture.gov.au Phone: 02 6272 2370	Name: Slava Zeman Email: slava.zeman@agriculture.gov.au Phone: 02 6272 3977
		OR Please contact exports@agriculture.gov.au if you have any queries.	

This advice replaces Market Access Advice MAA1711 issued on 6 February 2017. It contains important revised content which must be noted and minor typographical revisions. The important revised content is highlighted in yellow for your convenience.

As previously outlined the Department of Agriculture and Water Resources and China’s General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) have agreed on export certification for finished bovine blood products.

The department can issue government certification for exports of finished bovine blood products, derived **only from eligible Australian cattle** to China, effective immediately. Further information about the establishment approval process, product eligibility and export certification arrangements is provided below.

Negotiations with AQSIQ for the trade in semi-finished bovine blood products is ongoing. The department continues to work with AQSIQ as a matter of priority.

Establishment approval process

To be eligible to export finished bovine blood products to China, blood processing establishments producing finished blood products must be approved by both AQSIQ and the department. Requests for information about establishment approval should be directed to NPGExports@agriculture.gov.au

AQSIQ approval

AQSIQ's list of approved Australian establishments processing blood products for export to China is published on its website at:

http://dzwjyigs.aqsiq.gov.cn/fwdh n/qymd/gwjcp/gwqymd/201701/t20170120_481470.htm

AQSIQ establishment approvals are product specific – exporter and/or blood processing establishments must only export these approved blood products to China.

Department approval

Establishments that were audited and approved by AQSIQ and now intend to export finished bovine blood products to China must have a documented system addressing the key aspects of the blood protocol. **This includes a quality management system operating in conformance to ISO 9000: 2015 – Quality Management. Refer www.iso.org/iso/iso_9000.**

As such, the department must first verify the establishment can demonstrate compliance with AQSIQ's requirement for finished bovine blood products to be sourced from outside Australia's bluetongue virus zone. Full compliance will result in the blood establishment's details in the Establishment Register (ER) being updated to reflect finished product and market.

Requirement for product to be derived from Australian cattle only

AQSIQ has not yet approved the use of imported bovine blood products sourced from New Zealand in finished bovine blood products exported from Australia.

Until further notice, government certification for finished bovine blood products for export to China can only be issued for finished blood derived from eligible Australian cattle.

The department will keep industry informed of further developments in relation to access for bovine blood products derived from New Zealand cattle.

Export certification arrangements

There must be no hand writing on the certificate. Exporters must submit certificates with typed text only. The only handwriting permitted on the manual certificate will be the name, date, location and signature of the veterinarian.

Due to differences in test methodologies, different certificate templates have been developed to address the variety of scenarios.

These are manual certificates that must be obtained through your regional office.

Exporters must determine which certificate template reflects the methodologies that were used to test their product for bluetongue virus (BTV), bovine leukaemia virus (BLV) and bovine viral diarrhoea virus (BVDV). This is to be determined prior to contacting the regional office to request the certificate.

Summary of export certification available for finished bovine blood products intended for China

Certificate	Test Items		
M551AM	BTV: Virus isolation	BVDV: Virus isolation	BLV: Virus isolation
M551BM	BTV: RT-PCR	BVDV: Virus isolation	BLV: Virus isolation
M551CM	BTV: Virus isolation	BVDV: RT-PCR	BLV: Virus isolation
M551DM	BTV: Virus isolation	BVDV: Virus isolation	BLV: RT-PCR
M551EM	BTV: RT-PCR	BVDV: RT-PCR	BLV: Virus isolation
M551FM	BTV: Virus isolation	BVDV: RT-PCR	BLV: RT-PCR
M551GM	BTV: RT-PCR	BVDV: Virus isolation	BLV: RT-PCR
M551HM	BTV: RT-PCR	BVDV: RT-PCR	BLV: RT-PCR

The blood product must test negative to the appropriate test items used. Exporters must provide a copy of the laboratory report as supporting documentation when submitting the certificate.

If the product is irradiated, commercial documentation to support this treatment must be provided to the Chinese authorities with the consignment. Irradiation of the product does not remove the requirement for the product to undergo the testing procedures.

Further information about the export certification requirements for these products may be found in part 8.4 of the China section of the Manual of Importing Country Requirements (MICoR).

The information provided above is current at the time of writing and is intended for use as guidance only and should not be taken as definitive or exhaustive. The Commonwealth endeavours to keep information current and accurate, however, it may be subject to change without notice. Exporters are encouraged to verify these details with their importers prior to undertaking production/exports. The Commonwealth will not accept liability for any loss resulting from reliance on information contained in this notice.